The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET)
Kathryn M Field, Pramit M Phal, Greg Fitt, Christine Goh, Anna K Nowak, Mark A Rosenthal, John Simes, Elizabeth H Barnes, Kate Sawkins, Lawrence M Cher, Elizabeth J Hovey, Helen Wheeler
CANCER | WILEY | Published : 2017
BACKGROUND: Bevacizumab has been associated with prolonged progression-free survival for patients with recurrent glioblastoma; however, not all derive a benefit. An early indicator of efficacy or futility may allow early discontinuation for nonresponders. This study prospectively assessed the role of early magnetic resonance imaging (eMRI) and its correlation with subsequent routine magnetic resonance imaging (MRI) results and survival. METHODS: Patients were part of a randomized phase 2 clinical trial (CABARET) comparing bevacizumab with bevacizumab plus carboplatin for recurrent glioblastoma. eMRI was conducted after 4 weeks in the trial (after 2 treatments with bevacizumab [10 mg/kg every..View full abstract
Awarded by National Health and Medical Research Council
This was an investigator-driven study funded by Roche Products Pty Limited (Australia) and the National Health and Medical Research Council (grant 1037786). Funding was also received from Cancer Council New South Wales for translational research substudies conducted for this trial. Kathryn M Field was supported by a Stella Mary Langford Scholarship (University of Melbourne), the Royal Melbourne Hospital Research Medal, and the Watt-Geyer Memorial Research Fund.